AndreaBozzo/ceres-open-data-index huggingface dataset:
State Panel Discussion for Courts Data Exchange

In this presentation, the Children's Bureau's Division of State Systems (DSS) hosted a state panel discussion on building and maintaining a data exchange between courts and child welfare information systems. This discussion included a description and background of the state data exchanges in Utah, Alabama, District of Columbia, and Texas. The participants conversed about data security and use, maintenance and enhancements of the data exchanges, and lessons learned.

Note: Due to a weather event, the speakers for Alabama were unable to attend and therefore, DSS provided a speaker to present their materials.

The speakers for this panel were:
Utah:

Alabama:

District of Columbia:

Texas:

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E401065-T1: [Translated] ORAL PREPARATIONS CONTAINING HOST RESPONSE MODULATING ACTIVE INGREDIENTS

The present invention relates to topical oral care compositions comprising in a pharmaceutically acceptable carrier a safe and effective amount of a host-response modulating agent including one or more of an anti-oxidant and modifier of cell redox status, anti-inflammatory agent, metalloproteinase inhibitor, vitamins and nutrients key to maintenance of a host response balance and inhibitor of activation of NF-kB in combination with one or a mixture of additional oral therapeutic actives selected from antimicrobial/antiplaque agents, biofilm inhibiting agents, antibiotics; analgesics and local anesthetic agents; dentinal desensitizing agents and odor masking agents. The present compositions are effective in treating and preventing bacteria-mediated diseases present in the oral cavity and in mediating host reaction to the presence of pathogenic bacteria in the oral cavity as well as the toxins and endotoxins, inflammatory cytokines and mediators released or prompted by these oral pathogens. By controlling bacteria-mediated diseases and conditions present in the oral cavity and modulating host reaction, spread into the bloodstream and other parts of the body of pathogenic bacteria and associated harmful substances is prevented or minimized.
Selective alteration of gene expression in response to natural and synthetic retinoids.

Background
          Retinoids are very potent inducers of cellular differentiation and apoptosis, and are efficient anti-tumoral agents. Synthetic retinoids are designed to restrict their toxicity and side effects, mostly by increasing their selectivity toward each isotype of retinoic acids receptors (RARα,β, γ and RXRα, β, γ). We however previously showed that retinoids displayed very different abilities to activate retinoid-inducible reporter genes, and that these differential properties were correlated to the ability of a given ligand to promote SRC-1 recruitment by DNA-bound RXR:RAR heterodimers. This suggested that gene-selective modulation could be achieved by structurally distinct retinoids.
        
        
          Results
          Using the differential display mRNA technique, we identified several genes on the basis of their differential induction by natural or synthetic retinoids in human cervix adenocarcinoma cells. Furthermore, this differential ability to regulate promoter activities was also observed in murine P19 cells for the RARβ2 and CRABPII gene, showing conclusively that retinoid structure has a dramatic impact on the regulation of endogenous genes.
        
        
          Conclusions
          Our findings therefore show that some degree of selective induction or repression of gene expression may be achieved when using appropriately designed ligands for retinoic acid receptors, extending the concept of selective modulators from estrogen and peroxisome proliferator activated receptors to the class of retinoid receptors.
Patent AT-E400561-T1: [Translated] METHOD FOR PRODUCING SUBSTITUTED PHENYLSULFONYL UREAS FROM SULFOHALOGENES

N 1>-Phenylsulfonyl-N 2>-(pyrimidinyl or triazinyl)-urea derivatives are produced from phenylsulfonyl halides by ammonolysis, reaction of the resulting phenylsulfonamides with phosgene and condensation of the phenylsulfonyl isocyanates obtained with an aminopyrimidine or aminotriazole; selected solvent mixtures are used for the ammonolysis and/or condensation. Production of N 1>-phenylsulfonyl-N 2>-(pyrimidinyl or triazinyl)-urea derivatives comprises: (a) ammonolysis of a phenylsulfonyl halide (II) with ammonia, preferably (a1) in a solvent mixture comprising a 20:1 to 1:1, preferably 10:1-1.4:1, by weight mixture of optionally halogenated aromatic hydrocarbon(s) and polar aprotic solvent(s); (b) reaction of the resulting phenylsulfonamide (III) (with or without isolation) with phosgene, preferably (b1) in an organic solvent in the presence of a catalyst comprising isocyanate(s) of the formula R'-NCO (R = optionally substituted hydrocarbyl) and optionally a co-catalyst comprising an amine base; and (c) condensation of the phenylsulfonyl isocyanate (IV) obtained (with or without isolation) with an aminopyrimidine or aminotriazole (V) in an organic solvent; preferably (c1) in a solvent mixture comprising an optionally halogenated hydrocarbon of b.pt. above 110[deg]C and a polar aprotic solvent; provided that steps (a) and/or (c ) are carried out according to (a1) and/or (c1), respectively. [Image] Q : O; S; or N(R 4>); X* : H; halo; CN; NO 2; 1-3C alkyl; or OCH 3; X and Y : CH or N, but are not both CH; R : H; 1-12C alkyl; 2-10C alkenyl; 2-10C alkynyl; 1-6C alkyl substituted with 1-4 halo, 1-4C alkoxy, 1-4C alkylthio, CN, 1-4C alkoxy-CO and/or 2-6C alkenyl; 3-8C cycloalkyl optionally substituted with 1-4C alkyl, 1-4C alkoxy, 1-4C alkylthio and/or halo; 5-8C cycloalkenyl; phenyl-1-4C alkyl optionally ring-substituted with 1 or more halo, 1-4C alkyl, 1-4C alkoxy, 1-4C haloalkyl, 1-4C alkylthio, 1-4C alkoxy-CO, 1-4C alkyl-CO-O, CONH 2, 1-4C alkyl-CO-NH, 1-4C alkyl-NH-CO, (1-4C alkyl) 2N-CO and/or NO 2; 2-oxo-1,3-dioxolan-5-ylmethyl; 2,2-dimethyl-1,3-dioxolan-5-ylmethyl; 1,3-dioxolan-2-ylmethyl; or a group of formula (A-1)-(A-5): X : O; S; SO; or SO 2 and X 1> = CH 2; or X : CH 2 and X 1> = O; S; SO; or SO 2; X 2>O; S; SO; or SO 2; R 1>H or 1-3C alkyl; R 2>H; halo; or 1-3C alkyl or 1-3C alkoxy (both optionally substituted with 1 or more halo or 1-3C alkoxy); R 3>H; halo; 1-3C alkyl, 1-3C alkoxy or 1-3C alkylthio (each optionally substituted with 1 or more halo or optionally substituted with one or two 1-3C alkoxy or 1-3C alkylthio); NR 5>R 6>; 3-6C cycloalkyl; 2-4C alkenyl; 2-4C alkynyl; 3-4C alkenyloxy; or 3-4C alkynyloxy; R 4>H; 1-4C alkyl; or 1-4C alkoxy; R 5> and R 6>H; 1-4C alkyl; 3-4C alkenyl; 1-4C haloalkyl; or 1-4C alkoxy. Independent claims are also included for: (A) step (a) carried out under conditions (a1); (B) step (b) carried out using a phenylsulfonamide (III) with X* = halo and carried out under conditions (b1) (the co-catalyst can be a base other than an amine base); and (C) step (c) carried out under conditions (c1).
Training practitioners in preparing systematic reviews: a cross-sectional survey of participants in the Australasian Cochrane Centre training program

Background
          Although systematic reviews of health care interventions are an invaluable tool for health care providers and researchers, many potential authors never publish reviews. This study attempts to determine why some people with interest in performing systematic reviews do not subsequently publish a review; and what steps could possibly increase review completion.
        
        
          Methods
          Cross-sectional survey by email and facsimile of the 179 participants in Australasian Cochrane Centre training events between 1998 and 2000.
        
        
          Results
          Ninety-two participants responded to the survey (51 percent). Response rate of deliverable surveys was 82 percent (92/112). The remainder of the participants had invalid or no contact information on file. More than 75 percent of respondents felt that the current workshops met their needs for training. The most critical barriers to completion of a Cochrane review were: lack of time (80 percent), lack of financial support (36 percent), methodological problems (23 percent) and problems with group dynamics (10 percent).
        
        
          Conclusions
          Strategies to protect reviewer time and increase the efficiency of the review process may increase the numbers of trained reviewers completing a systematic review.
Information Memorandum (IM-01-08)

This Information Memorandum (IM) announces an amendment to Title IV-E Adoption Assistance for Children who are Voluntarily Relinquished to Private, Nonprofit Agencies (Amends Policy on Children who are Voluntarily Relinquished to a Private, Nonprofit Agency set forth in ACYF-CB-PA-01-01).

Metadata-only record linking to the original dataset. Open original dataset below.
2010 CMHS Uniform Reporting System (URS) Output Tables for Illinois

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 526817: 16-Hydroxy-nonadecanoic, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 16-[tert-butyl(dimethyl)silyl]oxynonadecanoate. Molecular Formula: C26H54O3Si. Molecular Weight: 442.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526056: trans-Ethyl-2-butyl-diazene

Chemical compound data from PubChem database. IUPAC Name: butan-2-yl(ethyl)diazene. Molecular Formula: C6H14N2. Molecular Weight: 114.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Network PUF - PY2016

The Network PUF (Ntwrk-PUF) is one of the seven files that make up the Marketplace PUF. The Ntwrk-PUF contains issuer-level data identifying provider network URLs. These data either originate from the Network ID template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
Compound 527351: 16,20,24-Trimethyl-tetratriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 17,21,25-trimethylhexatriacontanenitrile. Molecular Formula: C39H77N. Molecular Weight: 560.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
ARCHIVED: COVID-19 Hospitalizations Over Time

<strong> As of 9/12/2024, we will begin reporting on hospitalization data again using a new San Francisco specific dataset. Updated data can be accessed <u><a href="https://data.staff.sf.gov/Health-and-Social-Services/COVID-19-Hospital-Admissions-Over-Time/82gu-asz5/about_data">here.</a></u> </strong>

<strong>On 5/1/2024, hospitalization data reporting will change from mandatory to optional for all hospitals nationwide. We will be pausing the refresh of the underlying data beginning 5/2/2024. </strong>

<strong>A. SUMMARY</strong>
Count of COVID+ patients admitted to the hospital. Patients who are hospitalized and test positive for COVID-19 may  be admitted to an acute care bed (a regular hospital bed), or an intensive care unit (ICU) bed. This data shows the daily total count of COVID+ patients in these two bed types, and the data reflects totals from all San Francisco Hospitals.

<strong>B. HOW THE DATASET IS CREATED</strong>
Hospital information is based on admission data reported to the National Healthcare Safety Network (NHSN) and provided by the California Department of Public Health (CDPH).

<strong>C. UPDATE PROCESS</strong>
Updates automatically every week.

<strong>D. HOW TO USE THIS DATASET</strong>
Each record represents how many people were hospitalized on the date recorded in either an ICU bed or acute care bed (shown as Med/Surg under DPHCategory field).

The dataset shown here includes all San Francisco hospitals and updates weekly with data for the past Sunday-Saturday as information is collected and verified. Data may change as more current information becomes available.

<strong>E. CHANGE LOG</strong><UL><LI>9/12/2024 -Hospitalization data are now being tracked through a new source and are available <u><a href="https://data.staff.sf.gov/Health-and-Social-Services/COVID-19-Hospital-Admissions-Over-Time/82gu-asz5/about_data">here.</a></u>
<LI> 5/1/2024 - hospitalization data reporting to the National Healthcare Safety Network (NHSN) changed from mandatory to optional for all hospitals nationwide. We will be pausing the refresh of the underlying data beginning 5/2/2024. 
<LI> 12/14/2023 – added column “hospitalreportingpct” to indicate the percentage of hospitals who submitted data on each report date.
<LI> 8/7/2023 - In response to the end of the federal public health emergency on 5/11/2023 the California Hospital Association (CHA) stopped the collection and dissemination of COVID-19 hospitalization data. In alignment with the California Department of Public Health (CDPH), hospitalization data from 5/11/2023 onward are being pulled from the National Healthcare Safety Network (NHSN). The NHSN data is updated weekly and does not include information on COVID suspected (PUI) patients.
<LI> 4/9/2021 - dataset updated daily with a four-day data lag.</UL>
A comparison of balloon injury models of endovascular lesions in rat arteries

Background
          Balloon injury (BI) of the rat carotid artery (CCA) is widely used to study intimal hyperplasia (IH) and decrease in lumen diameter (LD), but CCA's small diameter impedes the evaluation of endovascular therapies. Therefore, we validated BI in the aorta (AA) and iliac artery (CIA) to compare it with CCA.
        
        
          Methods
          Rats underwent BI or a sham procedure (control). Light microscopic evaluation was performed either directly or at 1, 2, 3, 4 and 16 weeks follow-up. The area of IH and the change in LD (LD at 16 weeks minus LD post BI) were compared.
        
        
          Results
          In the BI-groups the area of IH increased to 0.14 ± 0.08 mm2 (CCA), 0.14 ± 0.03 mm2 (CIA) and 0.12 ± 0.04 mm2 (AA) at 16 weeks (NS). The LD decreased with 0.49 ± 0.07 mm (CCA), compared to 0.22 ± 0.07 mm (CIA) and 0.07 ± 0.10 mm (AA) at 16 weeks (p < 0.05). The constrictive vascular remodelling (CVR = wall circumference loss combined with a decrease in LD) was -0.17 ± 0.05 mm in CIA but absent in CCA and AA. No IH, no decrease in LD and no CVR was seen in the control groups.
        
        
          Conclusions
          BI resulted in: (1.) a decrease in LD in CCA due to IH, (2.) a decrease in LD in CIA due to IH and CVR, (3.) no change in LD in AA, (4.) Comparable IH development in all arteries, (5.) CCA has no vasa vasorum compared to CIA and AA, (6.) The CIA model combines good access for 2 F endovascular catheters with a decrease in LD due to IH and CVR after BI.
Compound 529879: Pyrazine, 2-[5-(hydroxymethyl)furfuryl]-3,6-dimethyl

Chemical compound data from PubChem database. IUPAC Name: [5-[(3,6-dimethylpyrazin-2-yl)methyl]furan-2-yl]methanol. Molecular Formula: C12H14N2O2. Molecular Weight: 218.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty

Background
          Although all patients undergoing total joint arthroplasty are subjected to similar risk factors that predispose to thromboembolism, only a subset of patients develop this complication. The objective of this study was to determine whether a specific genetic profile is associated with a higher risk of developing a postoperative thromboembolic complication. Specifically, we examined if the Factor V Leiden (FVL) mutation or the deletion polymorphism of the angiotensin-converting enzyme (ACE) gene increased a patient's risk for postoperative thromboembolic events. The FVL mutation has been associated with an increased risk of idiopathic thromboembolism and the deletion polymorphism of the ACE gene has been associated with increased vascular tone, attenuated fibrinolysis and increased platelet aggregation.
        
        
          Methods
          The presence of these genetic profiles was determined for 38 patients who had a postoperative symptomatic pulmonary embolus or proximal deep venous thrombosis and 241 control patients without thrombosis using molecular biological techniques.
        
        
          Results
          The Factor V Leiden mutation was present in none of the 38 experimental patients and in 3% or 8 of the 241 controls (p = 0.26). Similarly there was no difference detected in the distribution of polymorphisms for the ACE gene with the deletion-deletion genotype present in 36% or 13 of the 38 experimental patients and in 31% or 74 of the 241 controls (p = 0.32).
        
        
          Conclusions
          Our results suggest that neither of these potentially hypercoaguable states are associated with an increased risk of symptomatic thromboembolic events following total hip or knee arthroplasty in patients receiving pharmacological thromboprophylaxis.
Elk Creek Seismic Waveforms 2010 (Part 6 of 7)

Coal bursts (damaging seismic events in underground coal mines) pose a substantial threat to operations and mine workers. The underground coal mines in Colorado’s North Fork Valley (NFV) have experienced many coal bursts, often with distinct characteristics from those of other US coal mining regions. To better understand these events and manage their associated risks, the National Institute for Occupational Safety and Health undertook a long-term monitoring campaign at the Elk Creek Mine in the NFV. The monitoring efforts included a seismic network composed of both surface and underground sensors, borehole pressure cells (BPCs), instrumented support Cans, convergence monitors, ground condition surveys, and several other data sources. This dataset consists of the event waveform files from the seismic network for the 983,379 events that were detected during the monitoring campaign. The waveforms are stored in HDF5 files that are broken up by week. Within the HDF5 files, the data are organized by station id, event time, and channel. The amplitudes are velocity in meters/second.
 
This is download 7 of 48 and corresponds to the time range between December 6, 2010, and December 13, 2010.
Results from the 2013 National Survey on Drug Use and Health: Mental Health Detailed Tables

These detailed tables present results pertaining to mental health from the 2013 National Survey on Drug Use and Health (NSDUH), an annual survey of the civilian, noninstitutionalized population of the United States aged 12 years old or older. The detailed tables present national estimates of the prevalence of past year mental disorders and past year mental health service utilization for youths aged 12 to 17 and adults aged 18 or older. Among adults, estimates presented include rates and numbers of persons with any mental illness (AMI), serious mental illness (SMI), suicidal thoughts and behavior, major depressive episode (MDE), treatment for depression (among adults with MDE), and mental health service utilization. Estimates for youths include MDE, treatment for depression (among youths with MDE), and mental health service utilization. Measures related to the co-occurrence of mental disorders with substance use or with substance use disorders also are presented for both adults and youths. Results are provided by age group, gender, race/ethnicity, education level, employment status, county type, poverty level, insurance status, overal health, and geographic area. Comparisons are made between 2012 and 2011.
Compound 529026: Thiazole, 2-ethyl-4-methyl-5-propyl

Chemical compound data from PubChem database. IUPAC Name: 5-ethyl-3-methyl-2-propylthiophene. Molecular Formula: C10H16S. Molecular Weight: 168.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401574-T1: [Translated] ANALYSIS OF CIRCULATION TUMOR CELLS, FRAGMENTS AND DEBRIS

The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter3 fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
PubChem

PubChem contains the chemical structures of small organic molecules and information on their biological activities. PubChem includes substance information, compound structures, and bioactivity data in three primary databases, PCSubstance, PCCompound, and PCBioAssay, respectively. PubChem is integrated with Entrez, NCBI's primary search engine, and also provides compound neighboring, sub/superstructure, similarity structure, bioactivity data, and other searching features. Technical documentation at 	http://pubchem.ncbi.nlm.nih.gov/help.html#faq
A protein folding potential that places the native states of a large number of proteins near a local minimum

Background
          We present a simple method to train a potential function for the protein folding problem which, even though trained using a small number of proteins, is able to place a significantly large number of native conformations near a local minimum. The training relies on generating decoys by energy minimization of the native conformations using the current potential and using a physically meaningful objective function (derivative of energy with respect to torsion angles at the native conformation) during the quadratic programming to place the native conformation near a local minimum.
        
        
          Results
          We also compare the performance of three different types of energy functions and find that while the pairwise energy function is trainable, a solvation energy function by itself is untrainable if decoys are generated by minimizing the current potential starting at the native conformation. The best results are obtained when a pairwise interaction energy function is used with solvation energy function.
        
        
          Conclusions
          We are able to train a potential function using six proteins which places a total of 42 native conformations within ~4 Å rmsd and 71 native conformations within ~6 Å rmsd of a local minimum out of a total of 91 proteins. Furthermore, the threading test using the same 91 proteins ranks 89 native conformations to be first and the other two as second.